Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 376

1.

Getting away with phase transition: NPM1-mutated bone myeloid sarcoma mimicking Ewing sarcoma.

Marra A, Martino G, Ascani S, Martelli MP, Falini B.

Ann Hematol. 2019 Mar 16. doi: 10.1007/s00277-019-03664-4. [Epub ahead of print] No abstract available.

PMID:
30879096
2.

Hairy cell leukaemia mimicking multiple myeloma.

Notarfranchi L, Russo F, Re F, Mancini C, Martella E, Falini B, Aversa F, Tiacci E.

Lancet Oncol. 2019 Mar;20(3):e187. doi: 10.1016/S1470-2045(18)30609-0. No abstract available.

PMID:
30842062
3.

Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia.

Forghieri F, Riva G, Lagreca I, Barozzi P, Vallerini D, Morselli M, Paolini A, Bresciani P, Colaci E, Maccaferri M, Gilioli A, Nasillo V, Messerotti A, Pioli V, Arletti L, Giusti D, Bettelli F, Celli M, Donatelli F, Corradini G, Basso S, Gurrado A, Cellini M, Trenti T, Marasca R, Narni F, Martelli MP, Falini B, Potenza L, Luppi M, Comoli P.

Oncotarget. 2019 Jan 25;10(8):869-882. doi: 10.18632/oncotarget.26617. eCollection 2019 Jan 25.

4.

GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations.

Sportoletti P, Celani L, Varasano E, Rossi R, Sorcini D, Rompietti C, Strozzini F, Del Papa B, Guarente V, Spinozzi G, Cecchini D, Bereshchenko O, Haferlach T, Martelli MP, Falzetti F, Falini B.

Leukemia. 2019 Feb 12. doi: 10.1038/s41375-019-0399-7. [Epub ahead of print] No abstract available.

PMID:
30755706
5.

IDH1-R132 changes vary according to NPM1 and other mutations status in AML.

Falini B, Spinelli O, Meggendorfer M, Martelli MP, Bigerna B, Ascani S, Stein H, Rambaldi A, Haferlach T.

Leukemia. 2019 Jan 8. doi: 10.1038/s41375-018-0299-2. [Epub ahead of print] No abstract available.

PMID:
30622284
6.

Clonal Hematopoiesis Leading to AITL and NPM1-Mutated AML.

Tiacci E, Falini B.

N Engl J Med. 2018 Nov 29;379(22):2184-2185. doi: 10.1056/NEJMc1813168. No abstract available.

PMID:
30485779
7.

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target.

Sapienza MR, Abate F, Melle F, Orecchioni S, Fuligni F, Etebari M, Tabanelli V, Laginestra MA, Pileri A, Motta G, Rossi M, Agostinelli C, Sabattini E, Pimpinelli N, Truni M, Falini B, Cerroni L, Talarico G, Piccioni R, Amente S, Indio V, Tarantino G, Brundu F, Paulli M, Berti E, Facchetti F, Dellino GI, Bertolini F, Tripodo C, Rabadan R, Pileri SA.

Haematologica. 2018 Oct 31. pii: haematol.2018.202093. doi: 10.3324/haematol.2018.202093. [Epub ahead of print]

8.

Mutant NPM1 Maintains the Leukemic State through HOX Expression.

Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang YH, Ramabadran R, Gionfriddo I, Mezzasoma F, Milano F, Nabet B, Buckley DL, Kornblau SM, Lin CY, Sportoletti P, Martelli MP, Falini B, Goodell MA.

Cancer Cell. 2018 Sep 10;34(3):499-512.e9. doi: 10.1016/j.ccell.2018.08.005.

PMID:
30205049
9.

High-Risk Clonal Hematopoiesis as the Origin of AITL and NPM1-Mutated AML.

Tiacci E, Venanzi A, Ascani S, Marra A, Cardinali V, Martino G, Codoni V, Schiavoni G, Martelli MP, Falini B.

N Engl J Med. 2018 Sep 6;379(10):981-984. doi: 10.1056/NEJMc1806413. No abstract available.

PMID:
30184450
10.

A BRAF-mutated case of hairy cell leukaemia lacking Annexin-A1 expression.

Simonetti E, Ascani S, Volpetti S, Sabattini E, Falini B, Tiacci E.

Br J Haematol. 2018 Dec;183(5):702. doi: 10.1111/bjh.15502. Epub 2018 Jul 24. No abstract available.

PMID:
30043467
11.

Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates.

Gu X, Ebrahem Q, Mahfouz RZ, Hasipek M, Enane F, Radivoyevitch T, Rapin N, Przychodzen B, Hu Z, Balusu R, Cotta CV, Wald D, Argueta C, Landesman Y, Martelli MP, Falini B, Carraway H, Porse BT, Maciejewski J, Jha BK, Saunthararajah Y.

J Clin Invest. 2018 Oct 1;128(10):4260-4279. doi: 10.1172/JCI97117. Epub 2018 Jul 17.

12.

Recent advances in understanding and managing hairy cell leukemia.

Roider T, Falini B, Dietrich S.

F1000Res. 2018 Apr 27;7. pii: F1000 Faculty Rev-509. doi: 10.12688/f1000research.13265.1. eCollection 2018. Review.

13.

Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.

Tiacci E, Ladewig E, Schiavoni G, Penson A, Fortini E, Pettirossi V, Wang Y, Rosseto A, Venanzi A, Vlasevska S, Pacini R, Piattoni S, Tabarrini A, Pucciarini A, Bigerna B, Santi A, Gianni AM, Viviani S, Cabras A, Ascani S, Crescenzi B, Mecucci C, Pasqualucci L, Rabadan R, Falini B.

Blood. 2018 May 31;131(22):2454-2465. doi: 10.1182/blood-2017-11-814913. Epub 2018 Apr 12.

PMID:
29650799
14.

IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies.

Meggendorfer M, Cappelli LV, Walter W, Haferlach C, Kern W, Falini B, Haferlach T.

Leukemia. 2018 May;32(5):1249-1253. doi: 10.1038/s41375-018-0026-z. Epub 2018 Jan 30. No abstract available.

PMID:
29568090
15.

A scale of "bad" co-mutations in NPM1-driven AML.

Falini B, Sportoletti P.

Blood. 2017 Oct 26;130(17):1877-1879. doi: 10.1182/blood-2017-09-804062. No abstract available.

16.

Human monocyte-derived dendritic cells exposed to hyperthermia show a distinct gene expression profile and selective upregulation of IGFBP6.

Liso A, Castellani S, Massenzio F, Trotta R, Pucciarini A, Bigerna B, De Luca P, Zoppoli P, Castiglione F, Palumbo MC, Stracci F, Landriscina M, Specchia G, Bach LA, Conese M, Falini B.

Oncotarget. 2017 Jun 1;8(37):60826-60840. doi: 10.18632/oncotarget.18338. eCollection 2017 Sep 22.

17.

Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients.

De Clara E, Gourvest M, Ma H, Vergez F, Tosolini M, Dejean S, Demur C, Delabesse E, Recher C, Touriol C, Martelli MP, Falini B, Brousset P, Bousquet M.

Haematologica. 2017 Oct;102(10):1718-1726. doi: 10.3324/haematol.2017.171645. Epub 2017 Jul 4.

18.

Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling.

Tripodo C, Burocchi A, Piccaluga PP, Chiodoni C, Portararo P, Cappetti B, Botti L, Gulino A, Isidori A, Liso A, Visani G, Martelli MP, Falini B, Pandolfi PP, Colombo MP, Sangaletti S.

Cancer Res. 2017 Jul 1;77(13):3685-3699. doi: 10.1158/0008-5472.CAN-17-1098. Epub 2017 May 23.

19.

Genomics of Hairy Cell Leukemia.

Tiacci E, Pettirossi V, Schiavoni G, Falini B.

J Clin Oncol. 2017 Mar 20;35(9):1002-1010. doi: 10.1200/JCO.2016.71.1556. Epub 2017 Feb 13. Review.

20.

Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study.

Rosti G, Petrini M, Bosi A, Galieni P, Bernardi D, Giglio G, Dorotea L, Falini B, Scelzi E, Veltri E, Castelli R, Longagnani C, Raggi T, Simonetti F.

Ther Adv Med Oncol. 2017 Jan;9(1):22-32. doi: 10.1177/1758834016670554. Epub 2016 Oct 22.

21.

Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin.

Brunetti L, Di Battista V, Venanzi A, Schiavoni G, Martelli MP, Ascani S, Mecucci C, Tiacci E, Falini B.

Leukemia. 2017 May;31(5):1238-1240. doi: 10.1038/leu.2017.38. Epub 2017 Jan 23. No abstract available.

PMID:
28111467
22.

All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature.

Forghieri F, Bigliardi S, Quadrelli C, Morselli M, Potenza L, Paolini A, Colaci E, Barozzi P, Zucchini P, Riva G, Vallerini D, Lagreca I, Marasca R, Narni F, Venditti A, Martelli MP, Falini B, Lo Coco F, Amadori S, Luppi M.

Clin Case Rep. 2016 Oct 24;4(12):1138-1146. eCollection 2016 Dec.

23.

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B.

Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30.

24.

BRAF V600E mutation in hairy cell leukemia: from bench to bedside.

Falini B, Martelli MP, Tiacci E.

Blood. 2016 Oct 13;128(15):1918-1927. Epub 2016 Aug 23. Review.

25.

A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.

Chiaretti S, Vitale A, Vignetti M, Piciocchi A, Fazi P, Elia L, Falini B, Ronco F, Ferrara F, De Fabritiis P, Luppi M, La Nasa G, Tedeschi A, Califano C, Fanin R, Dore F, Mandelli F, Meloni G, Foà R.

Haematologica. 2016 Dec;101(12):1544-1552. Epub 2016 Aug 11.

26.

The genetics of nodal marginal zone lymphoma.

Spina V, Khiabanian H, Messina M, Monti S, Cascione L, Bruscaggin A, Spaccarotella E, Holmes AB, Arcaini L, Lucioni M, Tabbò F, Zairis S, Diop F, Cerri M, Chiaretti S, Marasca R, Ponzoni M, Deaglio S, Ramponi A, Tiacci E, Pasqualucci L, Paulli M, Falini B, Inghirami G, Bertoni F, Foà R, Rabadan R, Gaidano G, Rossi D.

Blood. 2016 Sep 8;128(10):1362-73. doi: 10.1182/blood-2016-02-696757. Epub 2016 Jun 22.

27.

New mechanism of lymphoma-induced bone marrow aplasia.

Pierini A, Mancusi A, Terenzi A, Massei MS, Del Papa B, Zei T, Iacucci R, Falzetti F, Aversa F, Falini B, Ruggeri L, Velardi A.

Ann Hematol. 2016 May;95(6):1013-5. doi: 10.1007/s00277-016-2632-z. Epub 2016 Mar 9. No abstract available.

PMID:
26957358
28.

Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia.

Falini B, Martelli MP.

Best Pract Res Clin Haematol. 2015 Jun-Sep;28(2-3):90-7. doi: 10.1016/j.beha.2015.10.005. Epub 2015 Oct 22. Review.

PMID:
26590764
29.

Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts.

Scarfò I, Pellegrino E, Mereu E, Kwee I, Agnelli L, Bergaggio E, Garaffo G, Vitale N, Caputo M, Machiorlatti R, Circosta P, Abate F, Barreca A, Novero D, Mathew S, Rinaldi A, Tiacci E, Serra S, Deaglio S, Neri A, Falini B, Rabadan R, Bertoni F, Inghirami G, Piva R; European T-Cell Lymphoma Study Group.

Blood. 2016 Jan 14;127(2):221-32. doi: 10.1182/blood-2014-12-614503. Epub 2015 Oct 13.

30.

A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for IGHV-D-J rearrangements and BRAF-V600E mutation: lack of evidence for a common origin.

Cavalli M, Ilari C, Del Giudice I, Marinelli M, Della Starza I, De Propris MS, De Novi LA, Nunes V, Cafforio L, Raponi S, Mancini F, Mauro FR, Tiacci E, Falini B, Guarini A, Foà R.

Br J Haematol. 2016 Jul;174(2):329-31. doi: 10.1111/bjh.13770. Epub 2015 Oct 12. No abstract available.

PMID:
26455504
31.

Dactinomycin in NPM1-Mutated Acute Myeloid Leukemia.

Falini B, Brunetti L, Martelli MP.

N Engl J Med. 2015 Sep 17;373(12):1180-2. doi: 10.1056/NEJMc1509584. No abstract available.

PMID:
26376154
32.

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, Saven A, Varettoni M, Altman JK, Anastasia A, Grever MR, Ambrosetti A, Rai KR, Fraticelli V, Lacouture ME, Carella AM, Levine RL, Leoni P, Rambaldi A, Falzetti F, Ascani S, Capponi M, Martelli MP, Park CY, Pileri SA, Rosen N, Foà R, Berger MF, Zinzani PL, Abdel-Wahab O, Falini B, Tallman MS.

N Engl J Med. 2015 Oct 29;373(18):1733-47. doi: 10.1056/NEJMoa1506583. Epub 2015 Sep 9.

33.

Transformation of IGHV4-34+ hairy cell leukaemia-variant with U2AF1 mutation into a clonally-related high grade B-cell lymphoma responding to immunochemotherapy.

Zanelli M, Ragazzi M, Valli R, Piattoni S, Alvarez De Celis MI, Farnetti E, Orcioni GF, Longo R, Ascani S, Falini B, Tiacci E.

Br J Haematol. 2016 May;173(3):491-5. doi: 10.1111/bjh.13627. Epub 2015 Aug 25. No abstract available.

PMID:
26303517
34.

Acute Myeloid Leukemia With Recurrent Genetic Abnormalities Other Than Translocations.

Lin P, Falini B.

Am J Clin Pathol. 2015 Jul;144(1):19-28. doi: 10.1309/AJCP97BJBEVZEUIN. Review.

PMID:
26071459
35.

Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma--combined performance of multiple markers.

van den Brand M, Mathijssen JJ, Garcia-Garcia M, Hebeda KM, Groenen PJ, Falini B, Serrano S, van Krieken JH.

Haematologica. 2015 Sep;100(9):e358-60. doi: 10.3324/haematol.2014.120956. Epub 2015 Jun 11. No abstract available.

36.

Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.

Falini B, Sportoletti P, Brunetti L, Martelli MP.

Br J Haematol. 2015 Aug;170(3):305-22. doi: 10.1111/bjh.13409. Epub 2015 Apr 19. Review.

PMID:
25891481
37.

Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.

Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan WC, Iqbal J, Piris MA, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz LD, Mevellec L, Vialard JE, Piva R, Bertoni F, Rabadan R, Inghirami G; European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium “Genetics-Driven Targeted Management of Lymphoid Malignancies”.

Cancer Cell. 2015 Apr 13;27(4):516-32. doi: 10.1016/j.ccell.2015.03.006. Erratum in: Cancer Cell. 2015 May 11;27(5):744.

38.

NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

Forghieri F, Paolini A, Morselli M, Bigliardi S, Bonacorsi G, Leonardi G, Coluccio V, Maccaferri M, Fantuzzi V, Faglioni L, Colaci E, Soci F, Nasillo V, Messerotti A, Arletti L, Pioli V, Zucchini P, Quadrelli C, Corradini G, Giacobbi F, Vallerini D, Riva G, Barozzi P, Lagreca I, Marasca R, Narni F, Mecucci C, Ottaviani E, Martinelli G, Falini B, Luppi M, Potenza L.

Leuk Lymphoma. 2015;56(11):3222-6. doi: 10.3109/10428194.2015.1026900. Epub 2015 May 12. Review. No abstract available.

PMID:
25813079
39.

Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.

Martelli MP, Gionfriddo I, Mezzasoma F, Milano F, Pierangeli S, Mulas F, Pacini R, Tabarrini A, Pettirossi V, Rossi R, Vetro C, Brunetti L, Sportoletti P, Tiacci E, Di Raimondo F, Falini B.

Blood. 2015 May 28;125(22):3455-65. doi: 10.1182/blood-2014-11-611459. Epub 2015 Mar 20.

40.

A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.

Abate F, Todaro M, van der Krogt JA, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A, Novero D, Gaudiano M, Aliberti S, Di Giacomo F, Tousseyn T, Lasorsa E, Crescenzo R, Bessone L, Ficarra E, Acquaviva A, Rinaldi A, Ponzoni M, Longo DL, Aime S, Cheng M, Ruggeri B, Piccaluga PP, Pileri S, Tiacci E, Falini B, Pera-Gresely B, Cerchietti L, Iqbal J, Chan WC, Shultz LD, Kwee I, Piva R, Wlodarska I, Rabadan R, Bertoni F, Inghirami G; European T-cell Lymphoma Study Group.

Leukemia. 2015 Jun;29(6):1390-401. doi: 10.1038/leu.2014.347. Epub 2014 Dec 23.

41.

BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.

Pettirossi V, Santi A, Imperi E, Russo G, Pucciarini A, Bigerna B, Schiavoni G, Fortini E, Spanhol-Rosseto A, Sportoletti P, Mannucci R, Martelli MP, Klein-Hitpass L, Falini B, Tiacci E.

Blood. 2015 Feb 19;125(8):1207-16. doi: 10.1182/blood-2014-10-603100. Epub 2014 Dec 5.

42.

Identification of novel DNA-damage tolerance genes reveals regulation of translesion DNA synthesis by nucleophosmin.

Ziv O, Zeisel A, Mirlas-Neisberg N, Swain U, Nevo R, Ben-Chetrit N, Martelli MP, Rossi R, Schiesser S, Canman CE, Carell T, Geacintov NE, Falini B, Domany E, Livneh Z.

Nat Commun. 2014 Nov 25;5:5437. doi: 10.1038/ncomms6437.

43.

Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.

Sportoletti P, Varasano E, Rossi R, Mupo A, Tiacci E, Vassiliou G, Martelli MP, Falini B.

Leukemia. 2015 Feb;29(2):269-78. doi: 10.1038/leu.2014.257. Epub 2014 Sep 2. Review.

PMID:
25179729
44.

HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse.

Martelli MF, Di Ianni M, Ruggeri L, Falzetti F, Carotti A, Terenzi A, Pierini A, Massei MS, Amico L, Urbani E, Del Papa B, Zei T, Iacucci Ostini R, Cecchini D, Tognellini R, Reisner Y, Aversa F, Falini B, Velardi A.

Blood. 2014 Jul 24;124(4):638-44. doi: 10.1182/blood-2014-03-564401. Epub 2014 Jun 12.

45.

SAVI: a statistical algorithm for variant frequency identification.

Trifonov V, Pasqualucci L, Tiacci E, Falini B, Rabadan R.

BMC Syst Biol. 2013;7 Suppl 2:S2. doi: 10.1186/1752-0509-7-S2-S2. Epub 2013 Oct 14.

46.

"Designed" grafts for HLA-haploidentical stem cell transplantation.

Martelli MF, Di Ianni M, Ruggeri L, Pierini A, Falzetti F, Carotti A, Terenzi A, Reisner Y, Aversa F, Falini B, Velardi A.

Blood. 2014 Feb 13;123(7):967-73. doi: 10.1182/blood-2013-10-531764. Epub 2013 Dec 20.

47.

Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23).

Hasan SK, Barba G, Metzler M, Divona M, Ottone T, Cicconi L, Falini B, Mecucci C, Lo-Coco F.

Genes Chromosomes Cancer. 2014 Mar;53(3):248-54. doi: 10.1002/gcc.22135. Epub 2013 Dec 5.

PMID:
24310817
48.

IL-17-producing double-negative T cells are expanded in the peripheral blood, infiltrate the salivary gland and are partially resistant to corticosteroid therapy in patients with Sjögren's syndrome.

Alunno A, Bistoni O, Bartoloni Bocci E, Caterbi S, Bigerna B, Pucciarini A, Tabarrini A, Mannucci R, Beghelli D, Falini B, Gerli R.

Reumatismo. 2013 Oct 31;65(4):192-8. doi: 10.4081/reumatismo.2013.192.

PMID:
24192564
49.

Subclonal evolution of a classical Hodgkin lymphoma from a germinal center B-cell-derived mantle cell lymphoma.

Schneider S, Crescenzi B, Schneider M, Ascani S, Hartmann S, Hansmann ML, Falini B, Mecucci C, Tiacci E, Küppers R.

Int J Cancer. 2014 Feb 15;134(4):832-43. doi: 10.1002/ijc.28422. Epub 2013 Aug 29.

50.

Nodal reactive and neoplastic proliferation of monocytoid and marginal zone B cells: an immunoarchitectural and molecular study highlighting the relevance of IRTA1 and T-bet as positive markers.

Bob R, Falini B, Marafioti T, Paterson JC, Pileri S, Stein H.

Histopathology. 2013 Oct;63(4):482-98. doi: 10.1111/his.12160. Epub 2013 Jul 15.

PMID:
23855758

Supplemental Content

Loading ...
Support Center